His club have released a statement welcoming him back to the Nou Camp ahead of Barca's match with Celta Vigo on Saturday.
"He left on January 21 for treatment in New York and two months later, this week, Vilanova will leave the Big Apple to return to the Catalan capital.
"During his absence, Jordi Roura took the reins of the team and was in constant contact with Vilanova, agreeing all decisions.
"We chose fourth grade because we feel that students at that age level are responsible enough and at an age where they can absorb the message," said Doreen Garza, UTPA College of Health and Human Sciences, Border Health Office Executive Director.
"It was geared toward their attention span. It doesn't move to fast, it doesn't move to slow. All of the higher order vocabulary, like pancreas for example, is spelled out with pictures and little graphics they can relate to," said Dr. Shawn Saladin, UTPA College of Health and Human Sciences Associate Dean.
The movie wasn't the only piece of information given out. Students also took home a small coloring assignment and more importantly, a diabetes registry form to give to someone they know with diabetes.
A small study found people taking diabetes drugs such as for example Merck & Co.as Januvia were suffering from pancreatic cell growth. Photo is filed by associated Press People using diabetes drugs such as Merck & Co.as Januvia were suffering from pancreatic cell growth and injury that'll change dangerous, a small study found. The research, led by Alexandra Butler and Peter Butler of the University of California, Los Angeles, offers proof increased precancerous changes in diabetics using alleged incretin mimetics, Public Citizen, a public advocacy group, said in a statement today after the study was published. The Food and Drug Administration said this month it had been reviewing unpublished results by a number of educational experts suggesting precancerous cellular changes might be connected with Type 2 diabetes solutions referred to as incretin mimetics, which also include Bristol-Myers Squibb Co.as Byetta and Novo Nordisk A/Sas Victoza. aThese conclusions are in agreement with the rapidly increasing quantity of studies to the U.S. Food and Drug Administration of pancreatic cancer in individuals using these drugs compared with diabetics using different drugs,a Public Citizen said. Doctors have been concerned because the FDA said in 2007 it received a higher amount of studies of pancreatitis in patients using Byetta that this group of diabetes treatments may damage the pancreas. The firm issued an identical alert for Januvia in '09. An analysis of insurance records published last month in the log JAMA Internal Medicine revealed such drugs may possibly increase a useras risk of pancreatitis. These medicines were stopped by that hasnat from becoming multibillion-dollar drugs. An examination of pancreases from 20 diabetics confirmed a 40 percent escalation in pancreatic cells in addition to cell damage in the people treated with incretin therapy, todayas study found. Of the 20 pancreases, eight were from people using incretin therapy, while 12 were on different therapy, according to a report in Diabetes, a journal of the American Diabetes Association. Eight of the nine people getting incretin solutions for annually or more were using Whitehouse Station-based Merckas Januvia while the other was using Byetta, according to the study. The research indicated that in humans, incretin treatment resulted in amarkeda cell proliferation and injury, with a potential for progress in to cancer, the authors wrote. Merck disagrees with the studyas theory, is comfortable in the safety of its drug and hasnat viewed any link between it and pancreatitis or pancreatic cancer, Kelley Dougherty, a spokeswoman for the drugmaker, said in a statement. Shock might tell you that the FDA said a week ago that the FDA hasn't achieved any new ideas about safety risks with one of these medicines, and at this time patients should continue to simply take their medication as directed until they speak to their health care company, and health care services should continue to follow the prescribing information in the medicine labels,a Dougherty said. Januvia produced about $4.1 billion in 2012 worldwide sales, Merck has described. Ken Dominski, a for New York-based Bristol-Myers, declined to touch upon the studyas studies. For Byetta, exenatide, aan considerable nonclinical security known program was conducted to guide the marketing applications of exenatide twice daily and exenatide after weekly,a Dominski said within an e-mail. aIn those studies, exenatide government was not associated with any drug- related pancreatic tissue injury or toxicity in any species tested.a Byetta and its longer-acting model, Bydureon, had $227 million in 2012 income, Bristol-Myers reported. Victoza, also called liraglutide, is the fastest-growing product for Bagsvaerd, Denmark-based Novo, with income moving 58 per cent in 2012 to 9.5 billion kroner ($1.7 billion). The medication mimics a called GLP-1 to encourage normal insulin production. A Novo spokeswoman declined to touch upon the analysis revealed today.
Link: Most of World's Adults Consume Too Much Salt, Study Finds
By Agence France-PresseMonday, March 25, 2013 7:17 EDT Adults and nearly half as many teenagers are dying from cancer currently as did in the 1970s, in accordance with a report from Cancer Research UK revealed Monday. Deaths between 2008-2010 in this age group were around 300 a, down from 580 a year in the period 1975-1977. The largest development was in those diagnosed with leukaemia with more specialised remedies considered to be behind the decline, said the report, aCancer Statistics Report: Teenage and Young Adult Cancer.a The research unveiled that around 2,100 people aged 15-24 years old are clinically determined to have cancer annually in Britain. aItas great to see such a drop in how many young adults dying from some types of cancers during this time,a explained Simon Davies, leader of Teenage Cancer Trust. aHowever, many of the rarer cancers which affect young adults like sarcomas have made little or no improvement. aMore investment in unusual cancer study is urgently needed,a he warned.
More Info: Medical Products Recalled Due to Mold
Editor's note: This is another in a series of stories leading up to the American Diabetes Association's Tour de Cure in Suffolk on April 20.
Diabetes Alert Day is coming up next week, and the American Diabetes Association is urging everyone to find out if they are at risk or have already developed the disease.
Type 2 diabetes affects nearly 175,000 people in Hampton Roads, including about 53,000 who do not even know they have it. An additional one in three American adults has pre-diabetes.
Diabetes Alert Day, a project of the American Diabetes Association, is Tuesday. A free screening will be held in Suffolk for folks to find out their risk.
"Part of our mission at the American Diabetes Association is for people to know their risk for Type 2 diabetes," said Robin Kantor, a manager at the organization's South Hampton Roads chapter. "A lot of people wait until they have a complication — blurry vision, neuropathy in their feet — and that brings them to the doctor. At that point they already have a complication that isn't reversible."
Type 2 diabetes, the more common form of the disease, is caused when the pancreas does not produce enough insulin, a hormone that helps the body process sugar, or when the cells ignore the insulin. It differs from Type 1, which is caused when the pancreas stops producing insulin completely.
It is important for people to know their numbers to determine their risk factors for diabetes, Kantor said. High blood pressure, cholesterol and weight contribute to diabetes. Risk increases with age and lack of physical activity. Race is also a factor, with any race other than white being at increased risk. Men are at higher risk than women, but women who were diagnosed with gestational diabetes are at higher risk than those who were not. One of the best predictors of risk is family history, so people should know whether a biological parent or sibling has been diagnosed with diabetes.
"Studies have shown that Type 2 diabetes can be prevented or delayed by losing just seven percent of body weight (such as 15 pounds if you weigh 200) through regular physical activity (30 minutes a day, five days a week) and healthy eating," said Dr. Joseph Aloi, clinical director at Eastern Virginia Medical School's Strelitz Diabetes Center.
Tuesday's free screening — from 2 to 7 p.m. at the Suffolk Family YMCA, 2769 Godwin Blvd. — will test cholesterol and blood pressure, as well as A1C and blood glucose, which are indicators of whether a person is diabetic or pre-diabetic. Those tests will be provided by Eastern Virginia Medical School, while Bon Secours Hampton Roads Health System will provide body mass index tests, along with information on diabetes care.
The American Diabetes Association will hand out information on healthy living, along with resources available through the association.
"If you score a five or higher, it lets you know it's time to go to the doctor and get your A1C checked," Kantor said.
The late Venezuelan president implied that his enemies gave him cancer. Katherine Belov, an expert on transmissible cancer in Tasmanian devils, says that is unlikely—but not impossible
CANCER Pancreatic cancer cells, false color scanning electron micrograph Image: Anne Weston, LRI, CRUK. Wellcome Images
Venezuelan officials announced this week that they would investigate whether enemies could have deliberately infected late President Hugo Chávez with cancer. Chávez died on March 5, apparently of a heart attack, after battling cancer for two years.
When the former Venezuelan president was diagnosed with an undisclosed form of cancer in 2011, he speculated that his enemies could have given him the disease. He also implied that U.S. agents could have developed a technology to induce cancer, according to a CNN news story at the time. The U.S. State Department called the accusation "absurd."
The theory that someone could be infected with cancer is not biologically impossible, but it is unlikely. A healthy immune system will combat any foreign cells, including cancerous ones. Only three types of contagious cancers have been identified, and all occur in non-primates.
Scientific American spoke with Katherine Belov, professor of comparative genomics at the University of Sydney who studies a contagious cancer called Tasmanian devil facial tumor disease. She explains why contagious cancers are rare and whether cancer could infect another person.
What are contagious cancers?In humans, we know that you can catch viruses, like the human papillomavirus, which make you more likely to get cancer. [HPV can cause cervical cancer in women, and genital warts and anal cancer in men.] In humans, environmental causes play an important role, too—cigarette smoke and radiation exposure can cause cancer. However, we don't have any clear examples of [naturally occurring] transmissible cancers in humans.
There is a transmissible cancer in dogs. It's a sexually transmitted disease called canine transmissible venereal tumor, or CTVT. And there is also the Tasmanian devil facial tumor disease, which I work on. The devil's cancer causes large ulcerations in their mouth and around their jaw. When they fight—and they fight a lot—they are biting other animals, and the cancerous cells are implanting in other animals' wounds.
In both the Tasmanian devils and in the case of CTVT, the tumor evolved in really inbred populations of animals. There was a lack of diversity and so the cancer is genetically very similar to the animals it passes to.
Why does lack of diversity help the cancer jump from animal to animal?The cancer is transmitted to animals that are genetically similar to one another and also to the tumor. The immune system doesn't "see" it and doesn't mount an immune response. The cancer can then grow until it kills the animal.
Over time the devil's facial tumor disease would have encountered animals that were genetically dissimilar to it. But the cancer found a way to down-regulate [or produce fewer] cell-surface molecules, which are sort of red flags to the immune system in genetically different animals. These flags are part of the major histocompatibility complex [a set of molecules attached to cells that regulate interactions with immune cells]—they are MHC molecules. Without those special immune molecules the cancer is able to fly under the radar of the immune system and pass from animal to animal.
Researchers at the Stanford University School of Medicine and Microsoft Research have revealed that the Internet search history of consumers can yield information on the unreported side effects of drugs or drug combinations.
By analyzing 12 months of search history from 6 million Internet users who consented to share anonymized logs of their Web searches for research purposes, the team was able to pinpoint an interaction between two drugs that was unknown at the time of data collection.
"Seeking health information is a major use of the Internet now," said co-author of the new paper Russ Altman, MD, PhD, Stanford professor of bioengineering, of genetics and of medicine. "So we thought people are likely typing in drugs they are taking and the side effects they are experiencing and that there must be a way for us to use this data."
The goal of this and previous research is to find fast, accurate methods of determining when a drug or combination of drugs cause unexpected side effects in some patients. The U.S. Food and Drug Administration encourages physicians to report any possible side effects through the agency's Adverse Event Reporting System. Such reporting is voluntary, however, and relies on a patient or a physician noticing that something unusual has happened.
Altman's lab group had previously studied whether it was possible to comb through data from FDA reports to discover drug-drug interactions in an automated way. Using their data-mining methods on the FDA reports, the group reported in May 2011 that it had found a never-before-reported side effect of combining paroxetine, an antidepressant medication, and pravastatin, a cholesterol-lowering drug. When a patient was taking both paroxetine (marketed as Paxil) and pravastatin (marketed as Pravachol or Selektine), the researchers found that the patient's risk of developing hyperglycemia — high levels of blood glucose — was greater than the risk of hyperglycemia from taking either drug individually.
Altman and his colleagues wondered whether they could have pinpointed the side effect any other way, since the adverse-event reports they relied on for the original discovery are only generated when a doctor takes the initiative and believes the side effect warrants reporting.
"Historically, it's been really hard to detect synergistic effects of drug combinations that aren't necessarily side effects of any of the drugs alone," Altman said.
Public Internet search history had previously been used to track flu outbreaks - a 2010 paper concluded that looking at the location and frequency of flu and flu-symptom-related searches was as accurate at following the flu's spread as the hospital-based-tracking methods used by the U.S. Centers for Disease Control and Prevention. To see whether a similar approach could work for detecting drug interactions and side effects, Altman teamed up with Nigam Shah, MBBS, PhD, assistant professor of medicine at Stanford. They collaborated with Eric Horvitz, MD, PhD, distinguished scientist and managing co-director at Microsoft Research; senior Microsoft researcher Ryen White, PhD, who is the study's lead author; and a colleague at Columbia University.
The Microsoft team developed automated tools for mining anonymized data from 82 million drug, symptom and condition searches performed by 6 million Internet users who had agreed, when they installed a Microsoft browser plugin, that the company could use their search history for research purposes.
White said the team used the automated tools to identify searches for information on paroxetine, pravastatin or both during 2010. The tools then computed the likelihood that users in each group would also search for hyperglycemia — or almost 80 of its symptoms or descriptors, such as "high blood sugar," "blurry vision," "frequent urination" or "dehydration."
"We really had to take into consideration this difficulty in predicting people's language," said Altman. "We could miss things because, through no fault of their own, the public doesn't know medical jargon."
Among people who searched for the drug paroxetine or its brand names in 2010, about 5 percent also searched for one of the hyperglycemia-related terms. For pravastatin and its brand names, the rate was below 4 percent. But for those who searched for both drugs, suggesting that they might be taking both drugs, the search rate for hyperglycemia was 10 percent.
To test the accuracy of the search engine analysis, the team looked at 31 drug-drug interactions already known to cause hyperglycemia, and 31 interactions known to be safe. Overall, the drugs with known interactions led to more search queries on hyperglycemia. But the results also suggested that around 12 percent of users searching for drug combinations known to have no interactions also had an unusually high rate of hyperglycemia searches, which would lead researchers down dead ends if they pursued them.
"We were surprised how good the signal was," said Shah. "The challenge now is to figure out what application this has in continuous monitoring for such side effects."
One way to improve this false-positive rate, Altman and Shah agree, is to combine the search history data with other sources of data — social media, patient support forums and information from medical records and doctors. Shah and his team are already studying how to search in an automated way through anonymized versions of patients' electronic medical records to find drug interactions. If the mining of consumer search engine data is combined with other information — such as reports to the FDA and searches by doctors on professional medical search programs — it could provide lists of potential drug-drug interactions for researchers to look into more closely through traditional clinical trials, they say.
"If we cross-reference multiple data sources, then we can triangulate based on what doctors and patients are both concerned about," said Shah.
The search data will always be messy, Shah admitted, since an Internet user's search history doesn't tell the complete story. Users could perform one search on their own symptoms, and the next on a symptom or drug related to someone else in their household, for example. In addition, a news story on a known or suspected drug-drug interaction could lead to excessive searches on that side effect, artificially inflating the results. But even if the data are messy, he said, enough messy data — like millions of search records — can reveal directions for researchers to pursue.
"I believe patients are telling us lots of things about drugs, and we need to figure out ways to listen," said Altman. "This is just one way of listening and one application."
The study was funded in part by the National Institutes of Health (grants HG004028 and GM61374). Information about Stanford's Department of Medicine, which also supported the work, is available at http://medicine.stanford.edu.
More Info: Specialists believe that the economics of Apple is "a bubble"
